依普沙坦 T2531L

Product Introduction
Bioactivity


英文名: Eprosartan

描述: Eprosartan (SKF-108566J free base) 是一种具有选择性和竞争性的非肽类血管紧张素II受体拮抗剂，对AT1受体亚型具有高亲和力，可用作降压剂。Eprosartan 对血管紧张素 II 受体有抑制作用，在大鼠和人类肾上腺皮质膜中的 IC50 值分别为 9.2 nM 和 3.9 nM。

体外活性: Eprosartan (SKF-108566J) inhibits [125I]AII binding to human liver membranes with an IC50 of 1.7 nM and to rat mesenteric artery membranes with an IC50 of 1.5 nM. In rabbit aortic smooth muscle cells, Eprosartan causes a concentration-dependent inhibition of AII-induced increases in intracellular Ca2+ levels[1]

体内活性: In conscious normotensive rats, intravenous administration of Eprosartan (0.01-0.3 mg/kg) produced dose-dependent parallel shifts in the AII pressor dose-response curve. Intragastric or intraduodenal administration of Eprosartan (3-10 mg/kg) to conscious normotensive rats resulted in a dose-dependent inhibition of the pressor response to AII (250 ng/kg, i.v.). Significant inhibition of the pressor response to AII was observed for 3 hours at a dose of 10 mg/kg, intraduodenally[1].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 55 mg/mL (129.56 mM)


关键字: KF-108566J | Eprosartan

相关产品: Angiotensin II human acetate | Prosaikogenin G | Camellianin A | [Sar1, Ile8]-Angiotensin II | OPHIOPOGONIN D | Eprosartan Mesylate | Angiotensin II 5-valine TFA | Moexipril hydrochloride | ACT 178882 | Fosinopril sodium

相关库: FDA-Approved Drug Library | Drug Repurposing Compound Library | Approved Drug Library | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compounds Library Max | EMA Approved Drug Library | Bioactive Compound Library

依普沙坦 T2531L信息由TargetMol中国为您提供，如您想了解更多关于依普沙坦 T2531L报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途